ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2010
[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR) is a major molecular for target therapy. The epidermal growth factor receptor tyrosine kinase inhibitors (TKIs), gefitinib (Iressa) and erlotinib (Tarceva), are two prospective agents towards non-small cell lung cancer (NSCLC). Multi-center clinical studies showed that there were obvious differences between individuals by the treatment of EGFR-TKIs. EGFR status is the major factor that influences the outcome for the treatment by TKI. Exon mutations and amplification of EGFR molecule are the critical factors that predict good response to TKIs. On the other hand, KRAS mutations indicate the resistant to the TKIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.